TrialNature medicine2023

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.

Fernanda Mosele et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.